Royalty Pharma plc
Health
Performance
2.3
Risk
Sell
Buy
Curious about the Scores? Learn more.

Royalty Pharma plc stock rating and score history

All changes in ratings, performance and outlook tracked over time.

10.07.2026
Still low-risk, but small tremors appearing.
24.06.2026
From weak to decent. The first signs are finally showing.
24.06.2026
Picking up speed. Momentum turning positive.
20.08.2025
Health’s picking up. Numbers look cleaner, cash flow tighter.
RPRX
Royalty Pharma plc
59.97
+2.11%
2.3
Sell
Buy
Royalty Pharma plc

Royalty Pharma plc stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Royalty Pharma plc do? Business model and key facts

Get the full picture of Royalty Pharma plc: what it builds, where it operates, and how it makes money.

Royalty Pharma plc Profile

Sector: Healthcare

Industry: Medical - Pharmaceuticals

Employees (FY): 100

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

shop
Company facts
Pablo Legorreta
CEO
100
Employees worldwide
shop
Performance
61.82%
Last 12 months
55.64%
Last 5 years
shop
Growth
$2.38B
Revenue year
$1.32B
Net income
shop
Valuation
$25.30B
Market Cap
16.58
Price/Earnings Ratio

Stocks related to Royalty Pharma plc

Selected based on industry alignment and relative market positioning.

WBA
Walgreens Boots Alliance, Inc.
11.98
+0.50%
1.4
Sell
Buy
Walgreens Boots Alliance, Inc.
CORT
Corcept Therapeutics Incorporated
94.19
+3.37%
6.6
Sell
Buy
Corcept Therapeutics Incorporated
KNSA
Kiniksa Pharmaceuticals International, plc
79.44
+25.03%
3.7
Sell
Buy
Kiniksa Pharmaceuticals International, plc
LFMD
LifeMD, Inc.
3.84
-0.78%
9.3
Sell
Buy
LifeMD, Inc.

Events and news impacting Royalty Pharma plc stock

Earnings, coporate decisions and industry developments that can affect the share price.

Royalty Pharma plc fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.